Cargando…

Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: A pilot study comparing fibrin rich in growth factors and teriparatide

Objectives: The aim of this study is to describe and compare the evolution of recurrent bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients treated with plasma rich in growth factors or teriparatide. Material and Methods: Two different types of treatments were applied in patients di...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelaz, Alejandro, Junquera, Luis, Gallego, Lorena, García-Consuegra, Luis, Junquera, Sonsoles, Gómez, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medicina Oral S.L. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119305/
https://www.ncbi.nlm.nih.gov/pubmed/24608203
http://dx.doi.org/10.4317/medoral.19458
_version_ 1782328944169582592
author Pelaz, Alejandro
Junquera, Luis
Gallego, Lorena
García-Consuegra, Luis
Junquera, Sonsoles
Gómez, Carlos
author_facet Pelaz, Alejandro
Junquera, Luis
Gallego, Lorena
García-Consuegra, Luis
Junquera, Sonsoles
Gómez, Carlos
author_sort Pelaz, Alejandro
collection PubMed
description Objectives: The aim of this study is to describe and compare the evolution of recurrent bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients treated with plasma rich in growth factors or teriparatide. Material and Methods: Two different types of treatments were applied in patients diagnosed of recurrent BRONJ in a referral hospital for 1.100.000 inhabitants. In the group A, plasma rich in growth factors was applied during the surgery. In the group B, the treatment consisted in the subcutaneous administration of teriparatide. All the cases of BRONJ should meet the following conditions: recurrent BRONJ, impossibility of surgery in stage 3 Ruggiero classification and absence of diagnosed neoplastic disease. Clinical and radiographic evolution of the patients from both groups was observed. Results: Nine patients were included, 5 in group A and 4 in group B. All the patients were women on oral bis-phosphonate therapy for primary osteoporosis (5 patients) or osteoporosis-related to the use of corticosteroids (4 patients). Alendronate was the most common oral bisphosphonate associated with BRONJ in our study (four patients in group A and two in group B). The mean age was 72,8 years in the group A and 73,5 years in the group B. All the patients from group A showed a complete resolution of their BRONJ. Only one patient in the group B showed the same evolution. Conclusions: In our series, the plasma rich in growth factors showed better results than the teriparatide in the treatment of recurrent BRONJ. Key words:Osteonecrosis, oral bisphosphonate, treatment, teriparatide, plasma rich in growth factors.
format Online
Article
Text
id pubmed-4119305
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medicina Oral S.L.
record_format MEDLINE/PubMed
spelling pubmed-41193052014-08-14 Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: A pilot study comparing fibrin rich in growth factors and teriparatide Pelaz, Alejandro Junquera, Luis Gallego, Lorena García-Consuegra, Luis Junquera, Sonsoles Gómez, Carlos Med Oral Patol Oral Cir Bucal Research Objectives: The aim of this study is to describe and compare the evolution of recurrent bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients treated with plasma rich in growth factors or teriparatide. Material and Methods: Two different types of treatments were applied in patients diagnosed of recurrent BRONJ in a referral hospital for 1.100.000 inhabitants. In the group A, plasma rich in growth factors was applied during the surgery. In the group B, the treatment consisted in the subcutaneous administration of teriparatide. All the cases of BRONJ should meet the following conditions: recurrent BRONJ, impossibility of surgery in stage 3 Ruggiero classification and absence of diagnosed neoplastic disease. Clinical and radiographic evolution of the patients from both groups was observed. Results: Nine patients were included, 5 in group A and 4 in group B. All the patients were women on oral bis-phosphonate therapy for primary osteoporosis (5 patients) or osteoporosis-related to the use of corticosteroids (4 patients). Alendronate was the most common oral bisphosphonate associated with BRONJ in our study (four patients in group A and two in group B). The mean age was 72,8 years in the group A and 73,5 years in the group B. All the patients from group A showed a complete resolution of their BRONJ. Only one patient in the group B showed the same evolution. Conclusions: In our series, the plasma rich in growth factors showed better results than the teriparatide in the treatment of recurrent BRONJ. Key words:Osteonecrosis, oral bisphosphonate, treatment, teriparatide, plasma rich in growth factors. Medicina Oral S.L. 2014-07 2014-03-08 /pmc/articles/PMC4119305/ /pubmed/24608203 http://dx.doi.org/10.4317/medoral.19458 Text en Copyright: © 2014 Medicina Oral S.L. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Pelaz, Alejandro
Junquera, Luis
Gallego, Lorena
García-Consuegra, Luis
Junquera, Sonsoles
Gómez, Carlos
Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: A pilot study comparing fibrin rich in growth factors and teriparatide
title Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: A pilot study comparing fibrin rich in growth factors and teriparatide
title_full Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: A pilot study comparing fibrin rich in growth factors and teriparatide
title_fullStr Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: A pilot study comparing fibrin rich in growth factors and teriparatide
title_full_unstemmed Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: A pilot study comparing fibrin rich in growth factors and teriparatide
title_short Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: A pilot study comparing fibrin rich in growth factors and teriparatide
title_sort alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: a pilot study comparing fibrin rich in growth factors and teriparatide
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119305/
https://www.ncbi.nlm.nih.gov/pubmed/24608203
http://dx.doi.org/10.4317/medoral.19458
work_keys_str_mv AT pelazalejandro alternativetreatmentsfororalbisphosphonaterelatedosteonecrosisofthejawsapilotstudycomparingfibrinrichingrowthfactorsandteriparatide
AT junqueraluis alternativetreatmentsfororalbisphosphonaterelatedosteonecrosisofthejawsapilotstudycomparingfibrinrichingrowthfactorsandteriparatide
AT gallegolorena alternativetreatmentsfororalbisphosphonaterelatedosteonecrosisofthejawsapilotstudycomparingfibrinrichingrowthfactorsandteriparatide
AT garciaconsuegraluis alternativetreatmentsfororalbisphosphonaterelatedosteonecrosisofthejawsapilotstudycomparingfibrinrichingrowthfactorsandteriparatide
AT junquerasonsoles alternativetreatmentsfororalbisphosphonaterelatedosteonecrosisofthejawsapilotstudycomparingfibrinrichingrowthfactorsandteriparatide
AT gomezcarlos alternativetreatmentsfororalbisphosphonaterelatedosteonecrosisofthejawsapilotstudycomparingfibrinrichingrowthfactorsandteriparatide